[HTML][HTML] R-Roscovitine simultaneously targets both the p53 and NF-κB pathways and causes potentiation of apoptosis: implications in cancer therapy
ET Wong, CF Cheok, V Tergaonkar… - Cell Death & …, 2008 - nature.com
Abstract Seliciclib (CYC202, R-Roscovitine) is a 2, 6, 9-substituted purine analog that is
currently in phase II clinical trials as an anticancer agent. We show in this study that R …
currently in phase II clinical trials as an anticancer agent. We show in this study that R …
R-Roscovitine simultaneously targets both the p53 and NF-κB pathways and causes potentiation of apoptosis: Implications in cancer therapy
A Dey, E Wong, C Cheok, V Tergaonkar, D Lane - Clinical Cancer Research, 2007 - AACR
A38 The p53 and NF-κB pathways are two critical transcriptional regulatory networks
deregulated in various human ailments including cancer and there has been a lot of …
deregulated in various human ailments including cancer and there has been a lot of …
R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy.
A Dey, ET Wong, CF Cheok, V Tergaonkar… - Cell Death and …, 2007 - europepmc.org
Seliciclib (CYC202, R-Roscovitine) is a 2, 6, 9-substituted purine analog that is currently in
phase II clinical trials as an anticancer agent. We show in this study that R-Roscovitine can …
phase II clinical trials as an anticancer agent. We show in this study that R-Roscovitine can …
[PDF][PDF] R-Roscovitine simultaneously targets both the p53 and NF-jB pathways and causes potentiation of apoptosis: implications in cancer therapy
A Dey, ET Wong, CF Cheok… - Cell Death and …, 2008 - researchgate.net
1Laboratory of Cell Cycle Control, Institute of Molecular and Cell Biology, Proteos, 138673,
Singapore and 2Laboratory of NF-kB Signaling in Human Ailments* Corresponding authors …
Singapore and 2Laboratory of NF-kB Signaling in Human Ailments* Corresponding authors …
R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy
A Dey, ET Wong, CF Cheok… - Cell death and …, 2008 - pubmed.ncbi.nlm.nih.gov
Seliciclib (CYC202, R-Roscovitine) is a 2, 6, 9-substituted purine analog that is currently in
phase II clinical trials as an anticancer agent. We show in this study that R-Roscovitine can …
phase II clinical trials as an anticancer agent. We show in this study that R-Roscovitine can …
[引用][C] R-roscovitine simultaneously targets both the p53 and NF-κB pathways and causes potentiation of apoptosis: implications in cancer therapy
A DEY - Cell Death Differ., 2008 - cir.nii.ac.jp
R-roscovitine simultaneously targets both the p53 and NF-κB pathways and causes potentiation
of apoptosis : implications in cancer therapy | CiNii Research CiNii 国立情報学研究所 学術情報 …
of apoptosis : implications in cancer therapy | CiNii Research CiNii 国立情報学研究所 学術情報 …
R-Roscovitine simultaneously targets both the p53 and NF-κB pathways and causes potentiation of apoptosis: implications in cancer therapy.
A Dey, ET Wong, CF Cheok… - Cell Death & …, 2008 - search.ebscohost.com
Abstract Seliciclib (CYC202, R-Roscovitine) is a 2, 6, 9-substituted purine analog that is
currently in phase II clinical trials as an anticancer agent. We show in this study that R …
currently in phase II clinical trials as an anticancer agent. We show in this study that R …
R-Roscovitine simultaneously targets both the p53 and NF-κB pathways and causes potentiation of apoptosis: implications in cancer therapy.
A Dey, ET Wong, CF Cheok… - Cell Death & …, 2008 - search.ebscohost.com
Abstract Seliciclib (CYC202, R-Roscovitine) is a 2, 6, 9-substituted purine analog that is
currently in phase II clinical trials as an anticancer agent. We show in this study that R …
currently in phase II clinical trials as an anticancer agent. We show in this study that R …
[引用][C] R-Roscovitine simultaneously targets both the p53 and NF-κB pathways and causes potentiation of apoptosis: implications in cancer therapy
A Dey, ET Wong, CF Cheok, V Tergaonkar… - Cell Death & …, 2007 - cir.nii.ac.jp
R-Roscovitine simultaneously targets both the p53 and NF-κB pathways and causes
potentiation of apoptosis: implications in cancer therapy | CiNii Research CiNii 国立情報学 …
potentiation of apoptosis: implications in cancer therapy | CiNii Research CiNii 国立情報学 …